A5017537885- Bladder and Urothelial Cancer Treatments
- Prostate Cancer Treatment and Research
- Cancer Immunotherapy and Biomarkers
- Curcumin's Biomedical Applications
- Urinary and Genital Oncology Studies
- Cancer-related Molecular Pathways
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Multiple Myeloma Research and Treatments
- Ferroptosis and cancer prognosis
- Immunotherapy and Immune Responses
- Epigenetics and DNA Methylation
- Retinoids in leukemia and cellular processes
- Cancer, Lipids, and Metabolism
- Genetic factors in colorectal cancer
- PI3K/AKT/mTOR signaling in cancer
- Protein Degradation and Inhibitors
- MicroRNA in disease regulation
- Cancer, Stress, Anesthesia, and Immune Response
- Cancer, Hypoxia, and Metabolism
- Chemokine receptors and signaling
- Photodynamic Therapy Research Studies
- Genomics, phytochemicals, and oxidative stress
- Chemotherapy-induced organ toxicity mitigation
- Extracellular vesicles in disease
Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol
2014-2024
Institut Català d'Oncologia
2018-2024
Universitat de Barcelona
2014-2024
City Of Hope National Medical Center
2024
Hospital Universitari Germans Trias i Pujol
2023
Badalona Serveis Assistencials
2021
Institute of Predictive and Personalized Medicine of Cancer
2019-2020
Experimental Medicine and Biology Institute
2012
Consejo Nacional de Investigaciones Científicas y Técnicas
2012
Abstract Resistance to oxaliplatin (OXA) is a complex process affecting the outcomes of metastatic colorectal cancer (CRC) patients treated with this drug. De-regulation NF-κB signalling pathway has been proposed as an important mechanism involved in phenomenon. Here, we show that was hyperactivated vitro models OXA-acquired resistance but attenuated by addition Curcumin, non-toxic inhibitor. The concomitant combination Curcumin + OXA more effective and synergistic cell lines acquired OXA,...
Abstract Colorectal cancer (CRC) development and progression, one of the most common cancers globally, is supported by specific mechanisms to escape cell death despite chemotherapy, including cellular autophagy. Autophagy an evolutionarily highly conserved degradation pathway involved in a variety processes, such as maintenance homeostasis clearance foreign bodies, its imbalance associated with many diseases. However, role autophagy CRC progression remains controversial, it has dual...
BackgroundAndrogen deprivation therapy (ADT) with docetaxel (D) and/or antiandrogen receptor therapies (ARTs) are the standard in metastatic hormone-sensitive prostate cancer (mHSPC). Alterations tumor suppressor genes (TSGs) RB1, PTEN, and TP53 associated an aggressive evolution treatment resistance castration-resistant (CRPC).ObjectiveTo study clinical implications of TSG mRNA expression mHSPC patients.Design, setting, participantsThis is a multicenter retrospective biomarker patients....
Taxanes are the most active chemotherapy agents in metastatic castration-resistant prostate cancer (mCRPC) patients; yet, resistance occurs almost invariably, representing an important clinical challenge. Taxane-platinum combinations have shown benefit a subset of patients, but mechanistic basis and biomarkers remain elusive. To identify mechanisms response indicators for antitumor efficacy taxane-platinum mCRPC. Transcriptomic data from publicly available mCRPC dataset taxane-exposed...
Chemoresistance is the main cause of treatment failure in advanced colorectal cancer (CRC). However, molecular mechanisms underlying this phenomenon remain to be elucidated. In a previous work we identified low levels PKM2 as putative oxaliplatin-resistance marker HT29 CRC cell lines and also patients. order assess how influences oxaliplatin response cells, silenced using specific siRNAs HT29, SW480 HCT116 cells. MTT test demonstrated that silencing induced resistance cells sensitivity Same...
Background: Docetaxel remains the standard treatment for metastatic castration-resistant prostate cancer (mCRPC). However, resistance frequently emerges as a result of hyperactivation PI3K/AKT and MEK/ERK pathways. Therefore, inhibition these pathways presents potential therapeutic approach. In this study, we evaluated efficacy simultaneous in docetaxel-resistant mCRPC, both vitro vivo . Methods: Docetaxel-sensitive mCRPC cells were treated with selumetinib (MEK1/2 inhibitor), AZD8186...
In recent years, an increasing number of studies have shown that elevated expression cyclin dependent kinase (Cdk5) contributes to the oncogenic initiation and progression many types cancers. this study, we investigated pattern Cdk5 in colorectal cancer (CRC) cell lines a large tumor samples order evaluate its relevance pathogenesis possible use as prognostic marker. We found is highly expressed activated CRC silencing decreases their migration ability. tissues, overexpressed compared normal...
Background The high incidence and mortality rates of urothelial carcinoma mean it remains a significant global health concern. Its prevalence is notably pronounced in industrialized countries, with Spain registering one the highest incidences Europe. Treatment options are available for various stages bladder cancer. Moreover, management landscape this disease has been significantly transformed by rapid advances immunotherapy. Healthcare professionals who diagnose, treat, follow up cancer...
Neoadjuvant chemotherapy followed by a cystectomy is the standard treatment in muscle-invasive bladder cancer (MIBC). However, role of adjuvant setting remains controversial, and therefore new prognostic predictive biomarkers are needed to improve selection MIBC patients. While lipid metabolism has been related several biological processes many tumours, including cancer, no metabolic have identified as routine clinical practice. In this multicentre, retrospective study 198 patients treated...
Abstract Background: In previous work we have observed hyper-activation of the transcription factor (TF) NF-κB and an up-regulation Cyclin-dependent kinase 5 (CDK5) in human colorectal cancer cell lines with acquired resistance to oxaliplatin (OXA). Moreover, OXA treatment induced activation. Curcumin (diferuloylmethane, CURC), major active ingredient turmeric (Curcuma longa), without discernable toxicity, has been shown inhibit growth colon tumor cells vitro vivo partly by suppressing...
Bladder cancer (BC) is the tenth most common cancer, and its incidence steadily rising worldwide, with highest rates in developed countries. Neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy standard therapy for patients muscle-invasive bladder cancer. However, less than 50% of initially respond to this treatment nearly all them eventually develop resistance, which an important barrier long-term survival. Therefore, there urgent need understand mechanisms cisplatin...
In the phase II MAJA trial, maintenance therapy with vinflunine resulted in longer progression-free survival compared to best supportive care advanced urothelial cell carcinoma (aUCC) patients who did not progress after first-line platinum-based chemotherapy. However, despite an initial benefit observed some patients, unequivocal resistance appears which underlying mechanisms are presently unknown. We have performed gene expression and functional enrichment analyses shed light on discovery...